$SGMO
SANGAMO THERAPEUTICS, INC

2016 Q4 Form 10-Q Financial Statement

#000156459016026384 Filed on October 27, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $8.922M $2.823M $8.569M
YoY Change -2.18% -67.06% -30.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.860M $5.020M $4.560M
YoY Change -0.61% 10.09% 22.25%
% of Gross Profit
Research & Development $13.89M $17.01M $16.69M
YoY Change -30.24% 1.92% 2.46%
% of Gross Profit
Depreciation & Amortization $300.0K $200.0K $300.0K
YoY Change 0.0% -33.33% 200.0%
% of Gross Profit
Operating Expenses $18.75M $22.03M $21.25M
YoY Change -24.37% 3.65% 5.89%
Operating Profit -$12.69M
YoY Change
Interest Expense $220.0K $240.0K $100.0K
YoY Change 633.33% 140.0% -9.09%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.610M -$18.97M -$12.58M
YoY Change -38.59% 50.73% 66.79%
Income Tax $10.00K -$3.000K -$3.339M
% Of Pretax Income
Net Earnings -$9.624M -$18.97M -$9.245M
YoY Change -31.32% 105.14% 22.53%
Net Earnings / Revenue -107.87% -671.8% -107.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$136.0K -$268.6K -$132.4K
COMMON SHARES
Basic Shares Outstanding 70.62M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.5M $155.1M $219.3M
YoY Change -31.8% -29.29% 35.05%
Cash & Equivalents $22.06M $27.99M $34.29M
Short-Term Investments $120.5M $127.1M $185.0M
Other Short-Term Assets $1.800M $1.500M $1.000M
YoY Change 125.0% 50.0% 12.74%
Inventory
Prepaid Expenses
Receivables $5.000M $1.500M $7.000M
Other Receivables $200.0K $300.0K $400.0K
Total Short-Term Assets $149.6M $148.8M $227.7M
YoY Change -29.63% -34.65% 31.48%
LONG-TERM ASSETS
Property, Plant & Equipment $6.600M $4.900M $3.063M
YoY Change 126.34% 59.97% 95.59%
Goodwill $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $9.500M $0.00
YoY Change -100.0%
Other Assets $169.0K $200.0K $185.0K
YoY Change 11.18% 8.11% 71.3%
Total Long-Term Assets $8.291M $16.20M $4.833M
YoY Change 78.19% 235.2% -93.48%
TOTAL ASSETS
Total Short-Term Assets $149.6M $148.8M $227.7M
Total Long-Term Assets $8.291M $16.20M $4.833M
Total Assets $157.9M $165.0M $232.5M
YoY Change -27.32% -29.04% -6.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.580M $6.300M $8.900M
YoY Change -33.93% -29.21% 11.25%
Accrued Expenses $2.900M $2.800M $2.800M
YoY Change -6.45% 0.0% 3.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.29M $13.90M $22.10M
YoY Change -33.87% -37.1% 13.37%
LONG-TERM LIABILITIES
Long-Term Debt $3.900M $2.300M $0.00
YoY Change
Other Long-Term Liabilities $4.500M $5.000M $6.800M
YoY Change -4.26% -26.47% -60.0%
Total Long-Term Liabilities $8.400M $7.300M $6.800M
YoY Change 78.72% 7.35% -60.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.29M $13.90M $22.10M
Total Long-Term Liabilities $8.400M $7.300M $6.800M
Total Liabilities $21.70M $21.10M $29.00M
YoY Change -12.5% -27.24% -22.06%
SHAREHOLDERS EQUITY
Retained Earnings -$440.9M
YoY Change 19.41%
Common Stock $577.1M
YoY Change 2.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $136.2M $143.8M $203.6M
YoY Change
Total Liabilities & Shareholders Equity $157.9M $165.0M $232.5M
YoY Change -27.32% -29.03% -6.0%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$9.624M -$18.97M -$9.245M
YoY Change -31.32% 105.14% 22.53%
Depreciation, Depletion And Amortization $300.0K $200.0K $300.0K
YoY Change 0.0% -33.33% 200.0%
Cash From Operating Activities -$11.80M -$17.60M -$14.20M
YoY Change 29.67% 23.94% 144.83%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$100.0K -$200.0K
YoY Change 100.0% -50.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $6.500M $32.20M $22.20M
YoY Change -85.68% 45.05% -126.62%
Cash From Investing Activities $6.200M $32.10M $21.90M
YoY Change -86.31% 46.58% -126.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -500.0K 600.0K 15.80M
YoY Change -50.0% -96.2% 1216.67%
NET CHANGE
Cash From Operating Activities -11.80M -17.60M -14.20M
Cash From Investing Activities 6.200M 32.10M 21.90M
Cash From Financing Activities -500.0K 600.0K 15.80M
Net Change In Cash -6.100M 15.10M 23.50M
YoY Change -117.33% -35.74% -126.7%
FREE CASH FLOW
Cash From Operating Activities -$11.80M -$17.60M -$14.20M
Capital Expenditures -$200.0K -$100.0K -$200.0K
Free Cash Flow -$11.60M -$17.50M -$14.00M
YoY Change 28.89% 25.0% 145.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70623858
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
139518000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
754000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4087000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1800000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1870000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-27000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4087000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
534000
sgmo Proceeds From Claims Settlement
ProceedsFromClaimsSettlement
14452000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20652000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28257000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34287000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2202000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the first quarter of 2016, we revised the estimated performance period of the upfront Biogen license through June 2019. This change increased net loss by $0.9 million and $2.7 million for the three and nine months ended September 30, 2016, respectively. The change in the performance period also increased our basic net loss per share by $0.02 and $0.04 for the three and nine months ended September 30, 2016, respectively.</p></div>
CY2016Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
27115000
CY2016Q3 us-gaap Marketable Securities
MarketableSecurities
127102000
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
154217000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
65937000
CY2015Q4 us-gaap Marketable Securities
MarketableSecurities
139518000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
205455000
CY2016Q3 sgmo Assets Amortized Cost
AssetsAmortizedCost
154089000
CY2015Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
205440000
CY2016Q3 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
129000
CY2015Q4 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2016Q3 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2015Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2015Q4 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2015 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2735000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2828000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13128000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8664000
CY2015Q4 sgmo Build To Suit Lease Property Leased
BuildToSuitLeasePropertyLeased
41400
CY2015Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2015Q4 sgmo Operating Leases Number Of Extension Options
OperatingLeasesNumberOfExtensionOptions
2
CY2016Q3 sgmo Build To Suit Lease Costs Capitalized
BuildToSuitLeaseCostsCapitalized
2200000

Files In Submission

Name View Source Status
0001564590-16-026384-index-headers.html Edgar Link pending
0001564590-16-026384-index.html Edgar Link pending
0001564590-16-026384.txt Edgar Link pending
0001564590-16-026384-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201610272008456266083.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20160930.htm Edgar Link pending
sgmo-20160930.xml Edgar Link completed
sgmo-20160930.xsd Edgar Link pending
sgmo-20160930_cal.xml Edgar Link unprocessable
sgmo-20160930_def.xml Edgar Link unprocessable
sgmo-20160930_lab.xml Edgar Link unprocessable
sgmo-20160930_pre.xml Edgar Link unprocessable
sgmo-ex101_156.htm Edgar Link pending
sgmo-ex102_155.htm Edgar Link pending
sgmo-ex103_154.htm Edgar Link pending
sgmo-ex311_7.htm Edgar Link pending
sgmo-ex312_9.htm Edgar Link pending
sgmo-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending